Journal of Radiation Research and Radiation Processing ›› 2020, Vol. 38 ›› Issue (4): 51-56.doi: 10.11889/j.1000-3436.2020.rrj.38.040302

• RADIOBIOLOGY AND RADIOMEDICINE • Previous Articles    

Dosimetric study on 3D-printing multi-channel applicator interstitial brachytherapy for cervical cancer

TAO Na,AN Yongwei,OUYANG Shuigen(),LUO Li,SUN Xiaoyan,ZHANG Chunlin,WEI Xiyi   

  1. Department of Radiotherapy, Gansu Provincial Cancer Hospital, Lanzhou 730050, China
  • Received:2020-03-12 Revised:2020-05-11 Accepted:2020-05-11 Online:2020-08-20 Published:2020-08-13
  • Contact: OUYANG Shuigen E-mail:ouyang328@126.com
  • About author:TAO Na (female) was born in November 1985, and graduated from Northwest Normal University in 2012, majoring in theoretical physics. Now she works at the Department of Radiation Oncology of Gansu Provincial Cancer Hospital as a medical physicist, engaging in medical physics of radiation therapy

Abstract:

In this study, we aimed to determine the dosimetric differences between 3D-printing multi-channel applicator interstitial brachytherapy (3DP-ISBT) and conventional three-dimensional intracavity treatment (ICBT) for cervical cancer with a high-risk clinical target volume (HR-CTV) of 50~90 cm3, to determine the feasibility of using 3DP-ISBT, and to provide a basis for the application of 3DP-ISBT in clinical practice. The study included 27 patients with cervical cancer and an HR-CTV of 50~90 cm3 who underwent radiotherapy at Gansu Provincial Cancer Hospital between May 2017 and May 2019. Among them, 14 patients were treated with 3DP-ISBT and 13 were treated with ICBT. With a prescription dose was 6 Gy, evaluated the volume of the HR-CTV, the dosimetric differences in D90 (received absorbed dose of 90% of the HR-CTV) of the HR-CTV, bladder, and rectum. Compared with the ICBT group, the 3DP-ISBT group showed no statistical differences in volume of the HR-CTV, D90 of the HR-CTV, and D1cc, D2cc, and D3cc of the rectum (doses received by 1 cm3, 2 cm3, and 3 cm3 of the rectal volume) (p>0.05). D1cc, D2cc, and D3cc of the bladder were lower in the 3DP-ISBT group than in the ICBT group, and the difference was statistically significant (p<0.05). 3DP-ISBT for cervical cancer with an HR-CTV volume of 50~90 cm3 can meet clinical requirements. The target can be irradiated with a sufficient dose in large-volume cancer and can protect the bladder better than can ICBT, however, there are no advantages in terms of protection of the rectum.

Key words: Cervical cancer, 3D printing multi-channel applicator, Intracavity treatment, Dosimetry

CLC Number: 

  • R815